Global IBS-C Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global IBS-C Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
IBS-C Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global IBS-C Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for IBS-C Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, IBS-C Drugs key manufacturers include Catalent Pharmaceuticals Solutions, Nestle, Abbott Laboratories, Synergy Pharmaceuticals, Sucampo Pharmaceuticals, Novartis Pharma Ag, Astellas Pharmaceuticals, Ardelyx, Inc and Synthetic Biologics, Inc, etc. Catalent Pharmaceuticals Solutions, Nestle, Abbott Laboratories are top 3 players and held % sales share in total in 2022.
IBS-C Drugs can be divided into Linaclotide, Lubiprostone, Osmotic Laxatives and Stimulant Laxatives, etc. Linaclotide is the mainstream product in the market, accounting for % sales share globally in 2022.
IBS-C Drugs is widely used in various fields, such as Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, etc. Hospital Pharmacies provides greatest supports to the IBS-C Drugs industry development. In 2022, global % sales of IBS-C Drugs went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global IBS-C Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Catalent Pharmaceuticals Solutions
Nestle
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Novartis Pharma Ag
Astellas Pharmaceuticals
Ardelyx, Inc
Synthetic Biologics, Inc
Teva Pharmaceutical Industries
Bama-Geve, SLU
Ferring BV
Ironwood Pharmaceuticals, Inc
Salix Pharmaceuticals Ltd
Norgine B.V
Prometheus Laboratories Inc
Actavis Nordic A/S
Albireo Pharma Inc
Yuhan Corp
Astrazeneca Plc
The Menarini Group
Ono Pharmaceutical Co., Ltd
Segment by Type
Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Others
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the IBS-C Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of IBS-C Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the IBS-C Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of IBS-C Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, IBS-C Drugs introduction, etc. IBS-C Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of IBS-C Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for IBS-C Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, IBS-C Drugs key manufacturers include Catalent Pharmaceuticals Solutions, Nestle, Abbott Laboratories, Synergy Pharmaceuticals, Sucampo Pharmaceuticals, Novartis Pharma Ag, Astellas Pharmaceuticals, Ardelyx, Inc and Synthetic Biologics, Inc, etc. Catalent Pharmaceuticals Solutions, Nestle, Abbott Laboratories are top 3 players and held % sales share in total in 2022.
IBS-C Drugs can be divided into Linaclotide, Lubiprostone, Osmotic Laxatives and Stimulant Laxatives, etc. Linaclotide is the mainstream product in the market, accounting for % sales share globally in 2022.
IBS-C Drugs is widely used in various fields, such as Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, etc. Hospital Pharmacies provides greatest supports to the IBS-C Drugs industry development. In 2022, global % sales of IBS-C Drugs went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global IBS-C Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Catalent Pharmaceuticals Solutions
Nestle
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Novartis Pharma Ag
Astellas Pharmaceuticals
Ardelyx, Inc
Synthetic Biologics, Inc
Teva Pharmaceutical Industries
Bama-Geve, SLU
Ferring BV
Ironwood Pharmaceuticals, Inc
Salix Pharmaceuticals Ltd
Norgine B.V
Prometheus Laboratories Inc
Actavis Nordic A/S
Albireo Pharma Inc
Yuhan Corp
Astrazeneca Plc
The Menarini Group
Ono Pharmaceutical Co., Ltd
Segment by Type
Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the IBS-C Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of IBS-C Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the IBS-C Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of IBS-C Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, IBS-C Drugs introduction, etc. IBS-C Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of IBS-C Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices